Smilax Laboratories Limited
Smilax Laboratories Limited is a Public Non-govt company company incorporated in 2004 and based in Telangana, India. Smilax Laboratories Limited operates in Manufacture of pharmaceuticals, medicinal chemicals and botanical products (NIC 24230) with authorized capital of ₹97.00 Cr and paid-up capital of ₹96.04 Cr. For 2022-23, the company reported revenue of ₹267.39 Cr and profit after tax of ₹3.77 Cr. The board has 3 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
Quick facts
Directors
3 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 21 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +8d | filed |
| MGT-7 | FY2023-24 | 22 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 24 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Smilax Laboratories Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 681602298 | Kotak Mahindra Bank Ltd(Bank) | ₹2.09 Cr | 19 Sep 2021 | Satisfied |
| 962838270 | HDFC Bank Ltd(Bank) | ₹2.15 Cr | 12 Mar 2020 | Satisfied |
| 744110455 | Kotak Mahindra Bank Ltd(Bank) | ₹11.17 Cr | 19 Sep 2022 | Open |
| 614104799 | HDFC Bank Ltd(Bank) | ₹15.53 Cr | 12 Mar 2019 | Satisfied |
| 361221493 | Kotak Mahindra Bank Ltd(Bank) | ₹22.55 Cr | 12 Mar 2019 | Open |
Charge IDs, lenders & amounts for Smilax Laboratories Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2022-23 | — | ||||
| 2021-22 | — | ||||
| 2020-21 | — | ||||
| 2019-20 | — | ||||
| 2017-18 | — | ||||
| 2016-17 | — |
Detailed Financials
4 FYs| Line item | 2022-23 | 2021-22 | 2020-21 | 2019-20 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2022-23 | +56.0% | +45.0% | +91.0% | |
| Profit after Tax2022-23 | — | — | — | |
| Net Worth2022-23 | +2.0% | -7.0% | +7.0% |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2016-17 | -9.22% | — | -14.31% | -4.10% | — | |||
| 2017-18 | -12.29% | +8.30% | -15.69% | -6.15% | — | |||
| 2019-20 | -0.51% | +24.18% | -0.82% | -0.35% | — | |||
| 2020-21 | +0.99% | +18.36% | +1.86% | +0.84% | — | |||
| 2021-22 | -6.42% | -14.72% | -11.41% | -4.93% | — | |||
| 2022-23 | +1.41% | +33.66% | +3.24% | +1.50% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 3 | 2,35,37,895 | 76.99% |
| Institutional Investors | 2 | 35,11,896 | 11.49% |
| Public & Others | 59 | 35,22,670 | 11.52% |
Promoter, institutional & public holding for Smilax Laboratories Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
9 peersTop 10 in Manufacture of pharmaceuticals, medicinal chemicals and botanical products
by healthView all ›Events & timeline
4External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.